Cellebrite DI Ltd. $CLBT Shares Purchased by Light Street Capital Management LLC

Light Street Capital Management LLC boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 104.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,312,755 shares of the company’s stock after purchasing an additional 671,830 shares during the period. Cellebrite DI makes up 2.1% of Light Street Capital Management LLC’s holdings, making the stock its 17th biggest holding. Light Street Capital Management LLC owned 0.53% of Cellebrite DI worth $19,166,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its holdings in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new stake in Cellebrite DI during the third quarter worth $40,000. CWM LLC increased its stake in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares during the last quarter. Elevation Wealth Partners LLC purchased a new stake in Cellebrite DI in the second quarter valued at $44,000. Finally, Vestcor Inc purchased a new stake in Cellebrite DI in the third quarter valued at $70,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CLBT. Lake Street Capital lowered their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. DA Davidson reduced their price objective on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. JPMorgan Chase & Co. decreased their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT remained flat at $11.45 during trading on Tuesday. The stock had a trading volume of 3,783,412 shares, compared to its average volume of 2,273,343. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.98. The stock has a fifty day moving average price of $14.00 and a 200-day moving average price of $13.65. The stock has a market capitalization of $2.86 billion, a P/E ratio of 52.05, a P/E/G ratio of 1.76 and a beta of 1.15.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the sale, the chief executive officer directly owned 790,548 shares in the company, valued at $12,166,533.72. This represents a 15.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CRO Marcus Jewell sold 12,562 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.24, for a total value of $141,196.88. Following the sale, the executive directly owned 427,128 shares in the company, valued at $4,800,918.72. This represents a 2.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 329,658 shares of company stock valued at $4,970,967. Insiders own 5.70% of the company’s stock.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.